Startup profile for Geneoscopy: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Geneoscopy funding, valuation and investors

GI diagnostics company — noninvasive colorectal cancer screening (ColoSense) and related tests.

Keep track of Geneoscopy

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series C

$105M · January 2025

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$105M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth · St. Louis, MO

Investors in latest funding

Lead: Bio-Rad Laboratories

Other: Petrichor , Labcorp , Morningside Ventures , Lightchain Capital

Sources: latest funding Last verified: 2026-07-26

Overview

Geneoscopy develops diagnostic tests for gastrointestinal health. Its lead product ColoSense is a noninvasive, stool-based colorectal cancer screening test using RNA biomarkers (with Bio-Rad Droplet Digital PCR technology cited in coverage). In January 2025 the St. Louis company closed a $105 million Series C led by Bio-Rad Laboratories, with Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, NT Investments, Granger Management/Mercy Health, Tri Locum Partners, and others. Proceeds support ColoSense commercialization and pipeline work including IBD-related diagnostics.

Why Geneoscopy is interesting

St. Louis GI diagnostics company that closed a $105M Series C (Jan 2025) led by Bio-Rad to commercialize ColoSense — RNA stool biomarker CRC screening with Labcorp distribution partnership.

Product & use cases

Stool-based molecular diagnostics for colorectal cancer screening and broader GI disease detection.

  • At-home CRC screening programs
  • Health-system screening pathways with Labcorp ordering
  • Future IBD diagnostic expansion

Key facts

  • Series C (Jan 2025): $105M led by Bio-Rad Laboratories (company / GenomeWeb)
  • Participants included Labcorp, Petrichor, Morningside Ventures, and others
  • Lead product: ColoSense noninvasive CRC screening
  • St. Louis, MO HQ

Funding history (newest first)

Series C

2025-01 $105M
  • Bio-Rad Laboratories (lead)
  • Petrichor (participant)
  • Labcorp (participant)
  • Morningside Ventures (participant)
  • Lightchain Capital (participant)

Source: https://www.geneoscopy.com/geneoscopy-closes-105m-in-series-c-funding-round-to-power-next-generation-of-gastrointestinal-diagnostic-tests/

Competitive landscape

Edge: RNA biomarker CRC test with strategic capital and distribution from Bio-Rad and Labcorp.

  • Exact Sciences (Cologuard) direct

    Market-leading stool DNA CRC screening.

  • Guardant / blood-based CRC tests adjacent

    Blood-based screening alternatives.

  • Colonoscopy providers incumbent

    Gold-standard procedural screening.

Industries

Biotech & Life Sciences Healthtech

Related funding articles

Venture Capital Tracker pieces that cover Geneoscopy's financing or category context.

FAQs about Geneoscopy

Practical answers founders, operators, and investors typically search for.

Develops GI diagnostic tests, including ColoSense for noninvasive colorectal cancer screening.
St. Louis, MO.
$105M in January 2025 led by Bio-Rad Laboratories.
An at-home, stool-based CRC screening test using RNA biomarkers.
No — private as of July 2026.
growth (post–Series C).
Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, and others joined Bio-Rad.
https://www.geneoscopy.com
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.